BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

BIMZELX is the first approved biologic therapy to demonstrate superior, head-to-head ACR50 joint outcomes in psoriatic arthritis: 49.1% of those receiving BIMZELX vs 38.4% receiving risankizumab achieved the stringent ACR50 primary endpoint at Week 161 Improvements in secondary endpoints:...